Cargando…

Corticosteroids and COVID-19: What Could Be the Best Bet in Treating Active Glomerular Diseases in Patients With Concomitant Early COVID-19?

Detalles Bibliográficos
Autores principales:	Nayak, Saurabh, Bharati, Joyita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	by the National Kidney Foundation, Inc. 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521867/ https://www.ncbi.nlm.nih.gov/pubmed/32991947 http://dx.doi.org/10.1053/j.ajkd.2020.09.006

Ejemplares similares

Inhaled Corticosteroids and COVID-19
por: Lipworth, Brian, et al.
Publicado: (2020)

COVID-19 associated with concomitant mucormycosis and aspergillosis
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

COVID-19: could CT provide the best population level biomarker? Incidental COVID-19 in major trauma patients suggests higher than predicted rates of infection in London
por: Alhashmi, A., et al.
Publicado: (2021)

Cobrotoxin could be an effective therapeutic for COVID-19
por: Lin, Fang, et al.
Publicado: (2020)

Corticosteroids and the hyper-inflammatory phase of the COVID-19 disease
por: Taboada, Manuel, et al.
Publicado: (2020)

Caution against corticosteroid-based COVID-19 treatment
por: Tang, Chong, et al.
Publicado: (2020)

Caution When Comparing the Impact of Corticosteroids in COVID-19
por: Confalonieri, Marco, et al.
Publicado: (2021)

Corticosteroids for COVID-19: the search for an optimum duration of therapy
por: Mishra, Gyanshankar P, et al.
Publicado: (2021)

Reply to Lipworth et al.: Inhaled Corticosteroids and COVID-19
por: Maes, Tania, et al.
Publicado: (2020)

COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON
por: Casadevall, Arturo, et al.
Publicado: (2022)

Re: COVID-19: could CT provide the best population level biomarker? Incidental COVID-19 in major trauma patients suggests higher than predicted rates of infection in London. A reply
por: Adam, E.J., et al.
Publicado: (2021)

Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2021)

Compromised periodontal status could increase mortality for patients with COVID-19
por: Gupta, Shipra, et al.
Publicado: (2022)

Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19
por: Añón, José M., et al.
Publicado: (2021)

Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One
por: Kow, Chia Siang, et al.
Publicado: (2021)

Atypical Anti-Glomerular Basement Membrane Disease
por: Bharati, Joyita, et al.
Publicado: (2023)

How to make the best of NLRP3 inhibitors in patients with COVID-19?
por: Kow, Chia Siang, et al.
Publicado: (2023)

How NETosis could drive “Post-COVID-19 syndrome” among survivors
por: Sawadogo, Serge A., et al.
Publicado: (2020)

Accelerated progression of pulmonary tuberculosis in a COVID-19 patient after corticosteroid treatment
por: Liu, Wang-Da, et al.
Publicado: (2022)

Adjunctive corticosteroid treatment for organizing pneumonia in COVID-19 patients with persistent respiratory failure
por: Segala, Francesco Vladimiro, et al.
Publicado: (2021)

COVID-19 and upper respiratory tract: Collecting swab specimens from patients inhaling corticosteroids
por: Siniorakis, Eftychios, et al.
Publicado: (2020)

Erratum: COVID-19–related Genes in Sputum Cells in Asthma: Relationship to Demographic Features and Corticosteroids
por: Peters, Michael C.
Publicado: (2020)

The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply
por: Meduri, G. Umberto, et al.
Publicado: (2021)

SARS, MERS, and COVID-19: What's next?
por: Sharun, Khan
Publicado: (2020)

What comes next in the COVID-19 pandemic?
por: Fisher, Dale, et al.
Publicado: (2022)

COVID-19… What are drugs and strategies now?
por: Bellini, Valentina, et al.
Publicado: (2021)

The USA's response to the 2014 Ebola outbreak could have informed its COVID-19 response
por: Madad, Syra, et al.
Publicado: (2021)

Corticosteroids for critically ill COVID-19 patients with cytokine release syndrome: a limited case series
por: Yang, Stephen Su, et al.
Publicado: (2020)

Gut Dysbiosis Could Be a Major Factor for the Effects of Low-Grade Endotoxemia in COVID-19 Comment on: Low-Grade Endotoxemia and Thrombosis in COVID-19
por: Chen, Jiezhong, et al.
Publicado: (2022)

What chikungunya teaches us about COVID-19
por: Simon, Fabrice, et al.
Publicado: (2021)

Impact of COVID-19 Pandemic on Nephrology Training in an Academic Center in India: Looking Forward Through Online Teaching
por: Bharati, Joyita, et al.
Publicado: (2021)

Optimizing Best Vascular Access Practice in Patients on Dialysis during the COVID-19 Pandemic Period
por: Georgiadis, George S., et al.
Publicado: (2021)

Risk of hepatitis B reactivation associated with treatment against SARS-CoV-2 (COVID-19) with corticosteroids()
por: Varona Pérez, J., et al.
Publicado: (2020)

When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19
por: Almas, Talal, et al.
Publicado: (2021)

The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?
por: Ribeiro, Sandro Augusto, et al.
Publicado: (2020)

Critical Illness–induced Corticosteroid Insufficiency: What It Is Not and What It Could Be
por: Téblick, Arno, et al.
Publicado: (2022)

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19
por: Thevarajan, Irani, et al.
Publicado: (2020)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

Bet‐hedging and best‐bet strategies shape seed dormancy
por: Pausas, Juli G., et al.
Publicado: (2022)

What Is the Best Drug to Treat COVID-19? The Need for Randomized Controlled Trials
por: Ottaviani, Silvia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s9raa21runtmq35h8d3mvtntd9